Abound Bio | News

NEWS

Latest Media and Papers

06/10/2021

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments to be used in combination with Vor’s engineered hematopoietic stem cell (eHSC) platform, with the goal of generating novel treatment systems for patients fighting acute myeloid leukemia (AML) and other devastating forms of blood cancer.

10/12/2020

One small part of a human antibody has the potential to work as a drug for both prevention and therapy of COVID-19

Our company’s CSO, Dr. Dimitrov recently published an article on The Conversation, introducing ab8, a highly potent antibody fragment against COVID-19, to the general public. In this article, Dr. Dimitrov discussed the discovery of ab8, why it could be promising therapy against COVID-19 and how it can help us fight against this global pandemic. “Ultimately I hope that this tiny ab8 antibody domain could be mass-produced and then injected into people to either prevent infection – by binding to a spike protein of an invading coronavirus before it infected a human cell – or to reduce the severity of COVID-19 once they were sick. ” – Dr. Dimitrov

09/16/2020

Yufan Biotechnologies and Abound Bio Sign Multi-Year Agreement to Develop Next Generation CAR T-cell Therapies for Cancer

Yufan Biotechnologies has now partnered with AboundBio to direct CAR T-cells against cancer targets. The agreement covers 10 cancer targets over multiple years with shared inventorship and development rights for the new technologies.
09/15/2020

Company CEO, John Mellors and CSO, Dimiter Dimitrov joined UPMC COVID-19 Preparedness Press Briefing about Potential Anti-COVID-19 Drug

Scientists at UPMC and the University of Pittsburgh have created an anti-COVID-19 drug that treats and prevents infection from SARS-CoV-2 virus in animals. Abound Bio has licensed the drug for worldwide development. On September 15, company CEO John Mellors and CSO Dimiter Dimitrov joined the UPMC COVID-19 Preparedness Press Briefing.
06/16/2020

Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, the key interaction that drives infection. As described in a recent pre-print on bioRxiv, this antibody did not show off-target binding to any human proteins on the MPA and is being progressed for further development…

Kurt Gehlsen

Consultant, Strategic and Business Development

Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.